GlassScriptPhysician profile
John Robert Seyerle
NPI 1871566026
$7,690.56
in general payments reported to CMS, 2019-2025
30 companies · $2,028 in 2025
The $2,028 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $272 · 2020: $54.77 · 2021: $458 · 2022: $1,071 · 2023: $1,845 · 2024: $1,962 · 2025: $2,028.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,716 · Consulting Fee: $85.23 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,715.76 |
| Consulting Fee | $85.23 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,146.10 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,699.95 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Genzyme Corporation | $871.41 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $596.31 | 2021-2025 | Dupixent |
| Csl Behring | $342.09 | 2019-2025 | Hizentra, Haegarda, Privigen |
| Takeda Pharmaceuticals U.S.A., INC. | $222.31 | 2021-2025 | Cuvitru, Takhzyro, Eohilia |
| Covis Pharma Gmbh | $221.10 | 2019-2022 | |
| Pfizer INC. | $204.59 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $188.12 | 2021-2025 | |
| Amgen INC. | $159.98 | 2022-2025 | Tezspire |
| Adma Biomanufacturing LLC | $134.19 | 2022-2024 | |
| Genentech USA, INC. | $133.09 | 2022-2025 | Xolair |
| Blueprint Medicines Corporation | $125.52 | 2023-2025 | Ayvakit |
| Kaleo, INC. | $104.04 | 2022-2023 | Auvi-Q |
| Ars Pharmaceuticals Operations, INC. | $80.23 | 2025 | Neffy |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hikma Pharmaceuticals USA | $72.74 | 2022-2025 | Ryaltris |
| Hospira, INC. | $60.22 | 2024-2025 | |
| Optinose US, INC. | $54.47 | 2019-2023 | |
| Aimmune Therapeutics, INC. | $42.22 | 2021-2023 | |
| Octapharma USA, INC. | $30.39 | 2023 | Cutaquig |
| Teva Pharmaceuticals USA, INC. | $28.73 | 2021 | |
| Lilly USA, LLC | $27.55 | 2025 | Ebglyss, Taltz |
| Alk-Abello, INC | $24.85 | 2019-2022 | |
| Grifols USA, LLC | $22.31 | 2022 | |
| Phadia US INC. | $19.00 | 2023 | Immunocap |
| Biocryst US Sales Co., LLC | $17.55 | 2021 | |
| Merck Sharp & Dohme LLC | $17.20 | 2023 | |
| Cycle Pharmaceuticals INC | $16.82 | 2025 | Sajazir |
| Pharming Healthcare, INC. | $15.54 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Seyerle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.